Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia (PLAT-03)

Condition(s)
Leukemia

Age Group
0-9 years 10-17 years 18-26 years

Phase(s)
1

Biological treatment cell Biological
T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Trial Summary

This study will enroll patients who have been enrolled into study PLAT-02 and meet the entry criteria for study PLAT-03.

Patients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19 CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells decrease in number over time. Study PLAT-03 will test whether administering T cell antigen presenting cells (T-APCs) at intervals following treatment with CAR-T cells improves CD 19 CAR-T cell persistence and reduces the incidence of leukemia relapse.

Ages: 1 Year to 26 Years
Condition: CD 19+ Acute Leukemia
Status
Recruiting
Location(s)
Seattle Children's Hospital, Seattle, WA
Contact
Colleen Annesley, MD
206-987-2106